X4 Pharmaceuticals Inc (XFOR)
0.9292
-0.03
(-3.18%)
USD |
NASDAQ |
May 17, 16:00
0.9292
0.00 (0.00%)
After-Hours: 20:00
X4 Pharmaceuticals Research and Development Expense (Quarterly): 19.85M for March 31, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 19.85M |
| December 31, 2023 | 15.27M |
| September 30, 2023 | 19.08M |
| June 30, 2023 | 15.60M |
| March 31, 2023 | 22.06M |
| December 31, 2022 | 19.01M |
| September 30, 2022 | 14.11M |
| June 30, 2022 | 13.82M |
| March 31, 2022 | 14.11M |
| December 31, 2021 | 12.16M |
| September 30, 2021 | 13.19M |
| June 30, 2021 | 13.19M |
| March 31, 2021 | 12.10M |
| December 31, 2020 | 12.30M |
| September 30, 2020 | 11.38M |
| Date | Value |
|---|---|
| June 30, 2020 | 9.342M |
| March 31, 2020 | 8.911M |
| December 31, 2019 | 7.065M |
| September 30, 2019 | 8.589M |
| June 30, 2019 | 8.854M |
| March 31, 2019 | 5.655M |
| December 31, 2018 | -6.289M |
| September 30, 2018 | 9.572M |
| June 30, 2018 | 8.93M |
| March 31, 2018 | 8.133M |
| December 31, 2017 | 9.23M |
| September 30, 2017 | 10.60M |
| June 30, 2017 | 3.906M |
| March 31, 2017 | 4.391M |
| December 31, 2016 | 4.227M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
7.065M
Minimum
Dec 2019
22.06M
Maximum
Mar 2023
13.50M
Average
13.19M
Median
Research and Development Expense (Quarterly) Benchmarks
| Phio Pharmaceuticals Corp | 1.148M |
| Ocular Therapeutix Inc | 20.74M |
| Alpine Immune Sciences Inc | 22.46M |
| Scholar Rock Holding Corp | 43.09M |
| RAPT Therapeutics Inc | 24.78M |